Saxenda® (liraglutide) – Expanded indication
December 4, 2020 - The FDA announced the approval of Novo Nordisk’s Saxenda (liraglutide), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older.
Download PDF
